This retrospective cohort study evaluated mortality and associated factors among people living with HIV (PLHIV) who were newly initiated on antiretroviral therapy (ART) at Bamenda Regional Hospital (BRH). The study population included individuals enrolled between January 2021 and December 2023, with data abstraction and analysis performed using R software version 4.3.1. A multivariable Cox proportional hazards model was used to identify predictors of mortality while adjusting for potential confounders.
The investigators conducted a retrospective cohort study at BRH. Enrollment was non-probabilistic using consecutive sampling. Data collection occurred from medical records using a structured questionnaire. The analysis timeframe and follow-up extended across the three-year enrollment window. Specific dates for data abstraction and detailed follow-up intervals beyond the study period were reported as part of the methods but full timing of follow-up visits was not detailed in the source.
A total of 331 participants newly initiated on ART were included. The mean age was 41.6 ± 11.7 years, and 57.7% of participants were female. Clinical, comorbidity, and laboratory data were extracted from facility records. The source states that variables showing statistical significance in univariable testing were entered into a multivariable Cox regression to evaluate relationships with mortality after adjustment.
Opportunistic diseases were recorded in 19.0% of participants, with tuberculosis representing 8.2% of cases. Reported comorbidities included hypertension (8.8%), diabetes (3.9%), and hepatitis B (3.0%). Laboratory findings reported in the cohort included mean liver enzyme levels (ALAT/ASAT) of 41.7 ± 23.6 U/L and mean blood glucose of 144.4 ± 7.4 mg/dL. Kidney function (creatinine mean 0.9 ± 0.2 mg/dL) and immune cell counts (lymphocytes mean 1.8 ± 0.7 x10^3/µL) were described as appearing normal overall.
Across the three-year period, the cumulative mortality rate observed in this cohort was 7.6%, which the authors approximate as roughly 2.5% per year. The study does not provide cause-of-death breakdowns in the source text, nor detailed timing of deaths relative to ART initiation beyond the aggregated cumulative rate.
In the adjusted Cox regression model, several factors were associated with increased hazard of death:
These predictors indicate that markers of more advanced clinical disease, concurrent illnesses, and abnormal laboratory indicators were independently associated with higher risk of death in this cohort.
The analysis found that body mass index (BMI) and ART adherence were not statistically significant predictors of mortality in the multivariable model as reported in the source. The source does not provide subgroup analyses or further stratified results for these variables.
The authors conclude that in this cohort of newly enrolled PLHIV at BRH, mortality was associated with advanced disease stage, the presence of opportunistic diseases, comorbid conditions, and abnormal laboratory findings such as elevated ALAT/ASAT. They recommend strengthening early diagnosis, active management of opportunistic infections, and routine monitoring of clinical and laboratory indicators to reduce mortality among PLHIV.
Ethical approval was obtained from the Institutional Review Board of the Catholic University of Central Africa (Ref: 2024/02082/CEIRSH/ESS/MSP). The authors declared no competing interests. The source is a medRxiv preprint posted July 20, 2026, and has not undergone peer review. The preprint notes that it reports new medical research that has yet to be evaluated and should not be used to guide clinical practice. Details on funding sources, cause-specific mortality, and granular timing of deaths were not reported in the source.